PURPOSE Abiraterone is an oral inhibitor of CYP17, which is essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with castration-resistant prostate cancer (CRPC), without prior chemotherapy or CYP17-targeted therapy, and frequency of bone scans discordant with prostate-specific antigen (PSA) and clinical response. EXPERIMENTAL DESIGN Thirty-three patie...

Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiratero...

Aim: Prostate cancer is the second leading cause of death in cancer-related deaths men. Docetaxel and abiraterone acetate are widely used treatment castration-resistant metastatic prostate cancer. Phospho-PTEN triggers proliferation, migration, angiogenesis survival cells by causing oncogenic Akt hyperactivation. This study, it aimed to investigate effects docetaxel agents, which cancer, on exp...

PURPOSE Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert Panel based recommendations a systematic literature review. Recommendations were approved by the and Clinical Practice Guidelines Committee. RESULTS Four clinical practice guidelines, one endorsement, 19 reviews with without meta-analy...

Androgen receptor axis-targeted agents (ARTAs), specifically enzalutamide and abiraterone acetate, have significantly extended the survival of men with metastatic castration-resistant prostate cancer (mCRPC), making them standard care for mCRPC. In addition, impact both drugs on health-related quality life (HRQoL) represents an important therapeutic objective mCRPC patients. This article aimed ...